GGrantIndex
← Leaderboards

Oncoceutics, Inc.

Philadelphia, PA

Compare ↔
$7,795,326
Total funding
3
Grants

Funding over time

peak $2.3M · FY2015–20
$2.5M$1.9M$1.3M$625K$0
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$6,552,469 · 2
FDA$1,242,857 · 1

By mechanism

R44$6,552,469 · 2
R01$1,242,857 · 1

Investigators at Oncoceutics, Inc.

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

1Joshua E. Allen$2,775,8502 gr2Martin Stogniew$496,5071 gr

All-Time

Most funded here, all years

1Wolfgang Oster$4,522,9693 gr2Joshua E. Allen$2,775,8502 gr3Martin Stogniew$496,5071 gr

Largest grants

Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma$999,600
R44 · FY2019 · CA
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma$999,600
R44 · FY2018 · CA
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma$999,250
R44 · FY2020 · CA
Clinical efficacy of the antitumor agent ONC201 in GBM$847,452
R44 · FY2015 · CA
Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer$777,000
R44 · FY2019 · CA
Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer$714,000
R44 · FY2018 · CA
Clinical efficacy of the antitumor agent ONC201 in GBM$552,548
R44 · FY2016 · CA
Phase I/II Trial of ONC201 for the Treatment of Multiple Myeloma IND121,496 (01/05/2015)$496,507
R01 · FY2019 · FD
Phase I/II Trial of ONC201 for the Treatment of Multiple Myeloma IND121,496 (01/05/2015)$496,399
R01 · FY2018 · FD
Phase I/II Trial of ONC201 for the Treatment of Multiple Myeloma IND121,496 (01/05/2015)$249,951
R01 · FY2016 · FD
Clinical efficacy of the antitumor agent ONC201 in GBM$224,700
R44 · FY2017 · CA
Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer$224,000
R44 · FY2017 · CA
Clinical efficacy of the antitumor agent ONC201 in GBM$210,000
R44 · FY2015 · CA
Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer$4,319
R44 · FY2018 · CA